KAI-1678 | CAS# 1041004-14-1 | inhibitor of epsilon protein kinase C

MedKoo Cat#: 414206 | Name: KAI-1678

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KAI-1678 is an inhibitor of epsilon protein kinase C (εPKC). KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.

Chemical Structure

KAI-1678

CAS#1041004-14-1

Theoretical Analysis

MedKoo Cat#: 414206

Name: KAI-1678

CAS#: 1041004-14-1

Chemical Formula: C107H190N44O28

Exact Mass: 2539.4796

Molecular Weight: 2540.98

Elemental Analysis: C, 50.58; H, 7.54; N, 24.25; O, 17.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

KAI-1678; KAI1678; KAI 1678; KP1678; KP 1678; KP-1678

IUPAC/Chemical Name

L-Argininamide, N-acetyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-seryl-L-leucyl-L-lysyl-L-prolyl-L-threonylglycylglycyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-

InChi Key

UVKJMACBAZMKAL-IAPYPFBNSA-N

InChi Code

InChI=1S/C107H190N44O28/c1-55(2)49-73(147-97(175)75(54-152)148-100(178)82(56(3)4)149-85(163)57(5)134-87(165)70(135-59(7)154)36-38-81(160)161)96(174)146-72(23-10-13-41-110)101(179)151-48-20-30-76(151)98(176)150-83(58(6)153)99(177)133-51-78(157)131-52-79(158)137-74(50-60-31-33-61(155)34-32-60)86(164)132-53-80(159)136-63(25-15-43-126-103(115)116)88(166)139-64(21-8-11-39-108)90(168)140-65(22-9-12-40-109)91(169)142-67(27-17-45-128-105(119)120)92(170)143-69(29-19-47-130-107(123)124)94(172)145-71(35-37-77(111)156)95(173)144-68(28-18-46-129-106(121)122)93(171)141-66(26-16-44-127-104(117)118)89(167)138-62(84(112)162)24-14-42-125-102(113)114/h31-34,55-58,62-76,82-83,152-153,155H,8-30,35-54,108-110H2,1-7H3,(H2,111,156)(H2,112,162)(H,131,157)(H,132,164)(H,133,177)(H,134,165)(H,135,154)(H,136,159)(H,137,158)(H,138,167)(H,139,166)(H,140,168)(H,141,171)(H,142,169)(H,143,170)(H,144,173)(H,145,172)(H,146,174)(H,147,175)(H,148,178)(H,149,163)(H,150,176)(H,160,161)(H4,113,114,125)(H4,115,116,126)(H4,117,118,127)(H4,119,120,128)(H4,121,122,129)(H4,123,124,130)/t57-,58+,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-,83-/m0/s1

SMILES Code

CC(C[C@@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(NCC(NCC(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCCN)=O)CCCNC(N)=N)=O)=O)Cc2ccc(O)cc2)=O)=O)=O)[C@H](O)C)=O)=O)CCCCN)=O)NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC(C)=O)CCC(O)=O)=O)C)=O)=O)CO)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 2,540.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Moodie JE, Bisley EJ, Huang S, Pickthorn K, Bell G. A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Med. 2013 Jun;14(6):916-24. doi: 10.1111/pme.12088. Epub 2013 Apr 8. PMID: 23565709. 2: Cousins MJ, Pickthorn K, Huang S, Critchley L, Bell G. The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain Med. 2013 Apr;14(4):533-40. doi: 10.1111/pme.12058. Epub 2013 Feb 25. PMID: 23438341. 3: Yonezawa T, Kurata R, Kimura M, Inoko H. PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101. doi: 10.2174/187221509788654205. PMID: 19519579.